Gen-Wealth Partners’s Pacific Biosciences PACB Stock Holding History

Gen-Wealth Partners’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$118	Hold	70	–	–	﹤0.01%	712
2026 Q1	$92	Hold	70	–	–	﹤0.01%	720
2025 Q4	$131	Hold	70	–	–	﹤0.01%	683
2025 Q3	$90	Hold	70	–	–	﹤0.01%	678
2025 Q2	$87	Hold	70	–	–	﹤0.01%	639
2025 Q1	$83	Hold	70	–	–	﹤0.01%	614
2024 Q4	$128	Hold	70	–	–	﹤0.01%	640
2024 Q3	$151	Hold	70	–	–	﹤0.01%	653
2024 Q2	$96	Hold	70	–	–	﹤0.01%	641
2024 Q1	$263	Buy	+70	New	+$410	﹤0.01%	618

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Gen-Wealth Partners's PACB Position: Q2 2026 in Review

Gen-Wealth Partners held its Pacific Biosciences (PACB) position steady in Q2 2026 at 70 shares worth $118. The position accounts for ﹤0.01% of the portfolio, ranked #712.

Gen-Wealth Partners first reported a position in PACB in Q1 2024 and has held it in 10 quarters since. The position peaked at $263 in Q1 2024. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Gen-Wealth Partners held 70 shares of Pacific Biosciences worth $118 as of Q2 2026.
Gen-Wealth Partners left its Pacific Biosciences share count unchanged in Q2 2026.
Pacific Biosciences made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q2 2026, its #712 holding.
Gen-Wealth Partners first reported a position in Pacific Biosciences in Q1 2024 and has held it in 10 quarters since.
Gen-Wealth Partners's Pacific Biosciences position peaked at $263 in Q1 2024.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Gen-Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.